Sedative, hypnotic or anxiolytic dependence with withdrawal delirium
ICD-10 F13.231 is a billable code used to indicate a diagnosis of sedative, hypnotic or anxiolytic dependence with withdrawal delirium.
F13.231 refers to a condition characterized by a dependence on sedative, hypnotic, or anxiolytic substances, accompanied by withdrawal delirium. This condition arises when an individual has developed a tolerance to these substances, leading to increased consumption to achieve the desired effects. Upon cessation or reduction of intake, withdrawal symptoms manifest, which can include severe agitation, confusion, hallucinations, and delirium. The clinical presentation may vary, but the hallmark of withdrawal delirium is a marked disturbance in consciousness and cognition, often requiring immediate medical intervention. Treatment typically involves supportive care, pharmacotherapy to manage symptoms, and rehabilitation programs aimed at addressing the underlying substance use disorder. Accurate diagnosis and coding are crucial for effective treatment planning and insurance reimbursement.
Detailed patient history, including substance use patterns and withdrawal symptoms.
Patients presenting with acute agitation, confusion, or hallucinations after cessation of sedative use.
Ensure thorough documentation of mental status examinations and any co-occurring psychiatric conditions.
Comprehensive assessment of substance use history and treatment plans.
Patients undergoing detoxification and rehabilitation for sedative dependence.
Document the multidisciplinary approach to treatment, including counseling and pharmacotherapy.
Used for follow-up visits for patients with documented sedative dependence.
Document the patient's history, current symptoms, and treatment plan.
Psychiatrists should ensure comprehensive mental status evaluations are included.
Key symptoms include confusion, agitation, hallucinations, and severe cognitive disturbances, which can pose significant risks to the patient.
